BIOCYTOGEN
25.3.2024 14:13:25 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Biocytogen’s RenLite® mice platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases. ABL’s consistent success in advancing its pipeline strongly showcases its expertise and capabilities in regulatory, clinical development, and business development activities. BsADC drugs derived from our RenLite® mice platform have shown preferable potency in various tumor models, while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which features increased tumor selectivity, target synergized internalization, and convenient CMC development, will complement ABL's capabilities effectively. Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs. This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About ABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325027750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany6.5.2026 13:01:00 CEST | Press release
-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” said Ludovic Fenaux, Senior Vice President, Vertex International. “This agreement represents significant progress for people living with these two devastating and life-shortening diseases. We are pleased to collaborate across the health c
Suzano Connects an Area the Size of Over 200,000 Soccer Fields Through Ecological Corridors in Just Four Years6.5.2026 13:00:00 CEST | Press release
Initiative integrates fragments of native forests in the Atlantic Forest, Cerrado and Amazon biomes, stimulating wildlife movement, the expansion of vegetation cover and the restoration of ecosystems Suzano, the world's largest pulp supplier, has connected 214,368 hectares of native forest in the Atlantic Forest, Cerrado, and Amazon biomes in Brazil by establishing ecological corridors, restoring an area larger than 200,000 soccer fields within four years. In 2025 alone, 55,366 hectares of native forest were connected, advancing Suzano’s public goal of connecting 500,000 hectares by 2030, as outlined in the Company’s recently published Sustainability Report. The implementation of ecological corridors is guided by decades of research and monitoring by Suzano and its partners. The aim is to connect larger fragments of land that host greater biodiversity, as well as those already monitored by experts, with sites where wildlife is limited or threatened. These corridors are designed to foll
NIQ Launches AI-Powered Platform to Help Brands Test Pricing Decisions Before They Go to Market6.5.2026 13:00:00 CEST | Press release
New AI-enabled solution replaces fragmented tools with simulation-driven pricing and promotion decisions before execution As manufacturers face mounting pressure to protect margins, justify trade spend, and respond faster to shifting consumer demand, NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the commercial launch of Price & Promo Optimizer, a next‑generation, AI‑enabled Revenue Growth Management (RGM) platform built to fundamentally change how pricing and promotion decisions are made. Today, many pricing and promotion decisions are still made across disconnected tools, manual workflows, and siloed teams—slowing execution, increasing risk, and limiting the ability to validate strategies before they reach the market. Price & Promo Optimizer replaces this fragmented approach with a united platform that brings pricing, promotion, and trade strategy into a single workflow. Powered by NIQ’s trusted store‑level measurement data and advanced analytical models,
From Checkout to Check-In: Klarna and Minor Hotels Bring Flexible Payments to Europe6.5.2026 12:56:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, and Minor Hotels, one of the world's leading hospitality groups, today announced a new partnership bringing Klarna's payments to travellers booking across Europe, just in time for the summer holiday season. With over 640 hotels, resorts and branded residences in operation and committed development across 63 countries, the group crafts innovative and insightful experiences through its hotel brands including Anantara, Elewana Collection, The Wolseley Hotels, Tivoli, Minor Reserve Collection, NH Collection, nhow, Avani, Colbert Collection, NH, Oaks, and iStay, as well as a diverse portfolio of restaurants and bars, travel experiences, and spa and wellness brands. Guests booking through Minor Hotel can now choose how they pay at checkout, whether that's paying immediately or splitting the cost into three interest-free installments, giving travellers greater financial flexibility when planning their dream trips. The partnership
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 20266.5.2026 12:30:00 CEST | Press release
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom